首页 | 本学科首页   官方微博 | 高级检索  
检索        

西咪替丁对肝癌射频消融患者细胞免疫功能的影响
引用本文:张发贵,王广田,庞志刚,刘超,郑立.西咪替丁对肝癌射频消融患者细胞免疫功能的影响[J].肝胆胰外科杂志,2006,18(2):83-85.
作者姓名:张发贵  王广田  庞志刚  刘超  郑立
作者单位:郑州大学第二附属医院普外科,郑州大学第二附属医院肝胆外科研究室,河南,郑州,450003
摘    要:目的研究西咪替丁(Cim)在短期内对肝癌射频消融(RFA)患者细胞免疫功能的影响。方法 39例肝癌患者随机分成RFA加Cim组(治疗组)和RFA组(对照组),用乳酸脱氢酶释放法测定入院时、RFA术前、术后第2天和第7天的NK细胞活性。结果 39例肝癌患者外周血NK细胞活性明显低于正常人(P< 0.01)。入院时和RFA术前治疗组与对照组间各基本指标无显著性差别(P>0.05)。术后第2天,两组NK 细胞活性均较入院时明显降低(P<0.05)。术后第7天,治疗组NK细胞活性较入院时和术后第2天明显增高 (P<0.01),治疗组NK细胞活性明显高于对照组(P<0.05)。结论肝癌患者细胞免疫功能下降,RFA术后细胞免疫功能进一步受到损害;Cim能在短期内增强机体的细胞免疫功能,可作为肝癌患者RFA术的一种重要辅助治疗。

关 键 词:西咪替丁  肝肿瘤  原发性  射频消融  NK细胞
文章编号:1007-1954(2006)02-0083-03
修稿时间:2005年12月12

Influence of cimetidine on cellular immunity after radiofrequency ablation in patients with primary liver cancer
ZHANG Fa-gui,WANG Guang-tian,PANG Zhi-gang,et al..Influence of cimetidine on cellular immunity after radiofrequency ablation in patients with primary liver cancer[J].Journal of Hepatopancreatobiliary Surgery,2006,18(2):83-85.
Authors:ZHANG Fa-gui  WANG Guang-tian  PANG Zhi-gang  
Institution:ZHANG Fa-gui,WANG Guang-tian,PANG Zhi-gang,et al.Dapartment of General Surgery,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450003
Abstract:Objective To study the influence of short-course cimetidine(Cim)on cellular immunity after radiofrequency ablation in patients with primary liver cancer(PLC). Methods Thirty-nine patients with PLC underwent radiofrequency ablation(RFA) at our hospital were randomized into a treatment group(took Cim) and a control group(did not take the drug).Natural killer cell(NKC) activity was measured at admission,before RFA,on the second and 7th day after RFA. Results Compared with normal control,the NKC activity in patients with PLC was significantly lower(P< 0.01). At admission and before RFA,the parameters were not significantly different between treatment group and control group(P> 0.05).while NKC activity on 7th day after RFA in treatment group was significantly higher than that in control group(P< 0.05).The NKC activity in both group were much lower on the second day after RFA than that before RFA(P< 0.01). Conclusion The cellular immunity is lower in PLC,and it is further damaged after RFA. Short-course Cim can boost the patients' cellular immunity and can serve as an important adjuvant in treatment of PLC patients during RFA.
Keywords:cimetidine  liver cancer  primary  radiofrequency ablation  natural killer cell
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号